← All science articles

· 2 min read

Yeast Study Compares How Two Bleomycin Drugs Break DNA Strands

By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Havdis Arctic PDRN95c against a stormy Norwegian coastline

Based on the PubMed abstract — the full text of this paper was not freely available.

Moore reported in Biochemistry (1990) that two closely related forms of the anticancer drug bleomycin, called A2 and B2, differ sharply in how many breaks they cause in DNA, and that this difference—not drug concentration alone—explains how much they kill cells.

The work used yeast (Saccharomyces cerevisiae) cells, some normal and some genetically altered to lack a working DNA ligase, the enzyme that reseals broken DNA strands. By labeling DNA with radioactive tracers and spinning it through a calibrated gradient, Moore counted the breaks each drug produced at various doses. Breaks rose roughly in step with drug dose, and surprisingly, cells with and without working ligase accumulated similar numbers of breaks, suggesting that under these conditions repair was not actively removing damage as it occurred. Bleomycin B2 caused considerably more breaks than bleomycin A2, even though the two molecules differ only in one chemical group.

This is laboratory chemistry and yeast genetics, not a human or animal study, and it says nothing about skin, wound healing, or therapeutic use of DNA fragments. It cannot show how these findings apply outside this specific experimental system.

Our reflection

This paper belongs to the decades of basic nucleic-acid chemistry that mapped, piece by piece, how DNA can be cut, repaired and studied at the molecular level—groundwork that today's polydeoxyribonucleotide research builds on. It has no direct bearing on skin or regenerative applications, but at Havdis, we see value in understanding this long history of rigorous DNA science.

Source

Moore CW (1990). Biochemistry.

Read the paper on PubMedDOI: 10.1021/bi00457a033

This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.

From research to ingredient

Developing with PDRN? Let’s talk.